查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1808306

移植HLA型檢測市場（按產品類型、技術、移植類型、應用和最終用戶分類）—2025-2030 年全球預測

HLA Typing for Transplant Market by Product Type, Technology, Transplant Type, Application, End user - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計移植HLA型檢測市場在 2024 年的價值將達到 10.8 億美元，在 2025 年成長至 11.8 億美元，在 2030 年達到 18.3 億美元，複合年成長率為 9.16%。

主要市場統計數據
基準年2024年 10.8億美元
預計2025年 11.8億美元
預測年份 2030 18.3億美元
複合年成長率（%） 9.16%

在過去十年中，組織分型已從手動血清學檢測發展到複雜的分子方法，能夠在傳統方法所需時間的一小部分內提供高度準確的結果。器官和幹細胞移植成功的關鍵在於準確識別人類白血球抗原 (HLA) 譜，這決定了供體與受體的相容性，並為免疫抑制方案提供參考。隨著全球移植數量的增加，對可靠、快速的HLA型檢測解決方案的需求也空前高漲。

聚合酵素鏈鎖反應技術與次世代定序技術的融合，推動了該領域的解析度達到前所未有的水平，使實驗室能夠以卓越的靈敏度檢測稀有等位基因和複雜單倍型。此外，流式細胞技術和高通量電泳平台的進步簡化了工作流程，縮短了周轉時間，並支持了關鍵的臨床決策。監管機構已為此建立了嚴格的標準和認證途徑，進一步確保了尖端方法的採用合法化。

此外，診斷技術與資訊學的融合營造了一個以數據主導的洞察來指導患者分層和風險評估的環境。移植生態系統中的相關人員，包括移植中心、診斷實驗室和研究機構，正在利用這些技術創新來最佳化配型流程並提高移植物存活率。本執行摘要將在以下章節中深入探討塑造移植HLA型檢測未來的變革性變化、這些變化對關稅、細分洞察和策略建議的影響。

深入分析顛覆性創新、技術突破和不斷發展的臨床工作流程，這些都影響移植中HLA型檢測的實踐

HLA型檢測方法的創新顛覆了傳統的診斷工作流程，從而提高了通量和品質。可攜式PCR系統和桌上型定序儀的出現使得高解析度分型變得普及，即使是規模較小的中心也能在現場進行複雜的檢測。此外，人工智慧和機器學習演算法與軟體平台的整合增強了基因型解讀能力，減少了人工干預，並最大限度地降低了人為錯誤的風險。

評估 2025 年美國關稅對供應鏈、採購成本和HLA型檢測可行性的深遠影響

美國將於2025年對進口檢測設備和耗材徵收關稅，這為診斷實驗室的籌資策略帶來了重大變數。對流式細胞儀、定序儀和電泳系統等高精度設備徵收的關稅推高了採購成本，迫使各機構重新評估供應商合約。此外，對試劑和專用耗材徵收的關稅也增加了每次檢測的成本，影響了移植中心和研究機構的預算分配。

透過詳細分析HLA型檢測產品類型、技術、移植、應用和最終用戶細分，提供策略見解

為了考慮市場細分，我們首先進行產品類型分析，涵蓋從硬體平台到軟體解決方案的各種產品。儀器是HLA型檢測工作流程的支柱，包括用於快速等位基因分離的電泳儀、針對高通量細胞分析最佳化的流式細胞儀、確保準確擴增的聚合酵素鏈鎖反應系統，以及能夠高解析度解碼複雜遺傳資訊的測序儀。與這些物理資產相輔相成的是支援檢測特異性和一致性的試劑和耗材，以及方便資料解讀、儲存和報告的專用軟體套件。

全面回顧美洲、歐洲、中東和非洲以及亞太地區HLA型檢測的區域動態、機會和挑戰

區域分析顯示，美洲、歐洲、中東和非洲以及亞太地區的發展軌跡各有不同，每個地區都受到其獨特的監管格局、醫療基礎設施和投資環境的影響。在美洲，完善的報銷途徑和成熟的移植中心網路正在推動先進HLA型檢測解決方案的早期應用。北美主要市場已從公共和私人對移植研究的資助中獲益匪淺，而拉丁美洲國家則正透過合作計畫和區域卓越中心逐步提升診斷能力。

對推動HLA型檢測生態系統進步、合作夥伴關係和競爭策略的關鍵組織的詳細評估

隨著競爭加劇，主要企業正透過策略夥伴關係關係、產品組合擴展和有針對性的創新等多種方式脫穎而出。領先的儀器製造商正在與軟體開發商合作，提供整合解決方案，以簡化樣品製備、數據收集和分析流程，從而縮短獲得結果的總時間。在試劑層面，各公司正在投資專有化學技術，以提高檢測靈敏度和可重複性，從而更可靠地檢測低頻等位基因。

提高營運效率、促進協作並加速在臨床環境中採用下一代HLA型檢測解決方案的策略建議

為了因應不斷發展的移植HLA型檢測市場，產業領導者應優先投資工作流程自動化和數位整合。採用模組化平台，實現快速分析擴展和無縫數據傳輸，使實驗室能夠在不影響品質的情況下實現更高的通量。此外，與試劑供應商和分銷合作夥伴建立策略聯盟可以降低供應鏈風險，並確保關鍵零件的持續供應。

一個強大的多階段研究途徑，詳細說明了HLA型檢測市場研究的資料收集、驗證通訊協定、分析框架和品管

本執行摘要依據的研究結合了主要研究方法和次要研究方法，旨在提供全面可靠的分析。主要研究包括對移植專業人員、實驗室主任和醫療採購專家的深入訪談，並輔以來自區域移植中心網路的調查資料。這種直接的接觸為跨地區的營運挑戰、應用促進因素和未滿足的需求提供了細緻的觀點。

核心研究結果的綜合，強調了移植HLA型檢測不斷發展的格局中的戰略重要性、未來前景以及相關人員的關鍵考慮因素

綜上所述，我們的核心研究結果表明，技術創新與臨床需求正在融合，重新定義移植領域HLA型檢測的模式。向高解析度分子偵測的轉變使得配型評估更加精準，而軟體和自動化則加快了周轉時間並減少了人為錯誤。同時，以2025年關稅上調為代表的貿易政策的不斷演變，正迫使相關人員重新評估籌資策略，並投資於供應鏈的韌性。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 全球捐贈者登記冊的擴大，加上巨量資料分析，將加強 HLA 配對預測模型。
  • 新型照護現場HLA型檢測平台加速器官移植中心的關鍵決策
  • 人工智慧演算法的整合簡化了移植實驗室中的 HLA 等位基因解釋
  • 次世代定序的引入將提高移植配型中高解析度HLA型檢測的準確性。
  • 單細胞定序技術的興起正在重塑供體-受體 HLA 匹配工作流程
  • 基於 CRISPR 的基因組編輯策略的實施針對 HLA 位點進行耐受性誘導研究。
  • 監管指南和標準化能力驗證將提高HLA型檢測品質管理計畫的一致性。
  • 超高通量微陣列解決方案的開發將降低成本並提高HLA型檢測分析的擴充性。
  • 非 HLA基因生物標記的重要性日益增加，將增強移植排斥管理中的風險分層
  • 轉向分散和自動化的 HLA 測試模型將減少移植前評估流程的周轉時間。

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

8. 移植HLA型檢測市場（依產品類型）

  • 裝置
    • 電泳設備
    • 流式細胞儀
    • PCR體系
    • 序列器
  • 試劑和耗材
  • 軟體

9. 移植HLA型檢測市場（依技術）

  • 分子檢測
    • 次世代定序（NGS）
    • 基於PCR的方法
    • 桑格定序
  • 非分子檢測
    • 混合淋巴球培養（MLC）
    • 血清學檢測

10. 移植HLA型檢測市場（依移植類型）

  • 造血幹細胞移植（HSCT）
    • 骨髓
    • 周邊血幹細胞
  • 固態器官移植
    • 心
    • 腎
    • 肝
    • 肺

第 11 章。移植HLA型檢測市場（依應用）

  • 疾病相關研究
  • 捐贈者和接受者的匹配
  • 藥物基因體學研究
  • 移植診斷

第 12 章。移植HLA型檢測市場（依最終用戶）

  • 血庫和器官捐贈組織
  • 診斷實驗室
  • 醫院及移植中心
  • 研究辦公室

13.美洲移植HLA型檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

14.歐洲、中東和非洲移植HLA型檢測市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

15.亞太地區移植HLA型檢測市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第16章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Agilent Technologies, Inc.
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • Abbott Laboratories
    • Biofortuna Limited
    • bioMerieux SA
    • Bruker Corporation
    • CareDx, Inc.
    • Creative Biolabs
    • Diasorin SpA
    • F. Hoffmann-La Roche Ltd
    • Fujirebio Inc.
    • GenDx BV
    • HistoGenetics LLC
    • Hologic, Inc.
    • Illumina, Inc.
    • Immucor, Inc. by WERFEN
    • Omixon Biocomputing Ltd.
    • PacBio
    • QIAGEN NV
    • Siemens Healthineers AG
    • Takara Bio Inc.
    • Thermo Fisher Scientific Inc.

第17章 研究人工智慧

第18章 研究統計

第19章 研究聯絡人

第20章 研究報導

第21章 附錄

Product Code: MRR-3D2FD205B873

The HLA Typing for Transplant Market was valued at USD 1.08 billion in 2024 and is projected to grow to USD 1.18 billion in 2025, with a CAGR of 9.16%, reaching USD 1.83 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.08 billion
Estimated Year [2025] USD 1.18 billion
Forecast Year [2030] USD 1.83 billion
CAGR (%) 9.16%

Over the past decade, histocompatibility testing has evolved from manual serological assays to sophisticated molecular approaches that deliver highly accurate results in a fraction of the time required by traditional methods. At the heart of successful organ and stem cell transplantation lies the precise identification of human leukocyte antigen (HLA) profiles, which dictates donor recipient compatibility and informs immunosuppressive regimens. As transplantation counts rise globally, the demand for reliable and rapid HLA typing solutions has never been greater.

The integration of polymerase chain reaction techniques with next-generation sequencing has propelled the field toward unprecedented resolution, enabling laboratories to detect rare alleles and complex haplotypes with superior sensitivity. Moreover, advancements in flow cytometry and high-throughput electrophoresis platforms have streamlined workflows and reduced turnaround times, supporting critical clinical decision making. Regulatory bodies have responded by establishing rigorous standards and accreditation pathways, further legitimizing the adoption of cutting-edge methodologies.

Furthermore, the convergence of diagnostic technologies with informatics has fostered an environment in which data-driven insights guide patient stratification and risk assessment. Stakeholders across the transplant ecosystem, including transplant centers, diagnostic laboratories, and research institutions, are leveraging these innovations to optimize matching processes and improve graft survival. In the following sections, this executive summary delves into transformative shifts, tariff impacts, segmentation insights, and strategic recommendations that will shape the future of HLA typing for transplant.

In-Depth Analysis of Disruptive Innovations, Technological Breakthroughs, and Evolving Clinical Workflows Shaping HLA Typing Practices Across Transplantation

Innovation in HLA typing methodologies has disrupted conventional diagnostic workflows, yielding improvements in throughput and quality. The advent of portable PCR systems and benchtop sequencers has democratized access to high-resolution typing, enabling smaller centers to conduct complex assays on site. In addition, the integration of artificial intelligence and machine learning algorithms into software platforms has enhanced genotype interpretation, reducing manual intervention and minimizing the risk of human error.

Furthermore, the migration toward cloud-based informatics solutions has accelerated data sharing among transplant networks, facilitating collaborative analysis and benchmarking. As laboratories adopt automated liquid handling and robotics, process variability has diminished and sample processing capacity has expanded, meeting the growing volumes of transplant evaluations. Regulatory frameworks are adapting in parallel, offering streamlined pathways for software-driven diagnostics while maintaining robust validation requirements.

Consequently, the landscape of HLA typing is becoming increasingly interconnected, with interoperable systems that link laboratory information management, electronic health records, and patient registries. These advancements not only improve clinical efficiency but also support real-time surveillance of transplant outcomes and population-level HLA diversity. In view of these trends, stakeholders must remain agile and embrace novel technologies to sustain competitive advantage and deliver superior patient care.

Evaluating the Far-Reaching Consequences of 2025 United States Tariffs on Supply Chains, Procurement Costs, and Operational Viability in HLA Typing

In 2025, the introduction of tariffs on imported laboratory instruments and consumables in the United States has introduced a significant variable into the procurement strategies of diagnostic laboratories. Tariffs applied to high-precision equipment such as flow cytometers, sequencers, and electrophoresis systems have driven up acquisition costs, compelling organizations to reevaluate vendor agreements. Moreover, duties on reagents and specialized consumables have translated into higher per-test expenses, affecting budget allocations for transplant centers and research facilities alike.

Supply chain resilience has become a paramount concern as manufacturers navigate shifting trade barriers and lead time uncertainties. Many laboratories have pursued alternative sourcing strategies, including partnerships with domestic suppliers or stockpiling critical reagents to mitigate potential shortages. In parallel, some instrument vendors have relocated certain production processes closer to end markets or introduced fee structures designed to offset the impact of import taxes.

These cumulative effects have created a dual imperative: laboratories must optimize resource utilization while maintaining the high accuracy and throughput standards that are essential for transplant compatibility assessments. As stakeholders adapt, collaborative purchasing consortia and local distribution hubs are emerging to leverage economies of scale and reduce the administrative burden associated with tariff compliance.

At the same time, the tariff environment has prompted a renewed focus on developing cost-effective consumables and open platform systems that offer greater flexibility in component sourcing. Strategic alliances between instrument manufacturers and local distributors are enabling a more agile response to regulatory changes, while cross-border collaborations seek to harmonize quality benchmarks and certification requirements. As the sector adjusts to this altered cost structure, long-term planning must incorporate scenario analyses that account for both tariff fluctuations and evolving global trade policies.

Illuminating Strategic Insights Through Detailed Analysis of Product, Technology, Transplant, Application, and End User Segmentation in HLA Typing

In considering market segmentation, the analysis begins with product categories that encompass a range of offerings from hardware platforms to software solutions. Instruments represent the backbone of HLA typing workflows and include electrophoresis equipment designed for rapid allele separation, flow cytometers optimized for high-throughput cell analysis, polymerase chain reaction systems that ensure precise amplification, and sequencers capable of decoding complex genetic information with high resolution. Complementing these physical assets are reagents and consumables that support assay specificity and consistency, as well as specialized software suites that facilitate data interpretation, storage, and reporting.

Technology segmentation distinguishes molecular assays, which leverage methodologies such as next-generation sequencing for comprehensive allele profiling, PCR-based techniques for targeted amplification, and Sanger sequencing for confirmatory analysis, from non-molecular assays that rely on mixed lymphocyte culture to assess cellular reactivity and serological approaches to detect antigen presence through antibody interactions. Each category delivers unique advantages in terms of throughput, cost, and resolution, catering to diverse laboratory requirements.

Transplant type segmentation draws a distinction between hematopoietic stem cell transplantation and solid organ transplantation. The former includes both bone marrow and peripheral blood stem cell applications, where rapid typing is critical to patient outcomes. The latter encompasses heart, kidney, liver, and lung transplants, each demanding tailored HLA matching criteria and risk assessment protocols. Application segmentation captures the spectrum of research and clinical use cases, spanning disease association studies that explore genetic predispositions, donor recipient matching processes that underpin graft acceptance, pharmacogenomics research informing individualized therapies, and transplant diagnostics that guide perioperative management.

Finally, end users range from blood banks and organ procurement organizations that manage donor registries to diagnostic laboratories equipped for high-complexity testing, hospitals and transplant centers overseeing patient pathways, and research laboratories driving innovation. Understanding these nuanced segments is essential for stakeholders seeking to align product development, marketing strategies, and service offerings with the specific needs and priorities of each customer group.

Comprehensive Examination of Regional Dynamics, Opportunities, and Challenges Across the Americas, Europe Middle East Africa, and Asia-Pacific in HLA Typing

Regional analysis reveals distinct trajectories across the Americas, Europe Middle East Africa, and Asia-Pacific, each shaped by unique regulatory landscapes, healthcare infrastructure, and investment climates. In the Americas, established reimbursement pathways and a mature network of transplant centers have fostered early adoption of advanced HLA typing solutions. Key markets in North America benefit from significant public and private funding for transplant research, while Latin American countries are gradually expanding diagnostic capacities through collaborative programs and regional centers of excellence.

In Europe, Middle East, and Africa, harmonization of regulatory standards within the European Union has accelerated the availability of novel assays, yet variability persists across member states in terms of coverage and reimbursement. In the Middle East, growing healthcare modernization initiatives and the establishment of specialized transplant units are driving demand for high-resolution typing, whereas resource constraints in parts of Africa underscore the need for scalable and cost-effective testing models.

Across the Asia-Pacific region, rapid investments in healthcare infrastructure and rising prevalence of transplant procedures are catalyzing market growth. Markets in East Asia demonstrate strong uptake of next-generation sequencing, supported by local manufacturing capabilities and research partnerships. Meanwhile, Southeast Asian countries are enhancing laboratory networks through government-led health reforms, and Australasia continues to lead in the integration of informatics platforms that link transplant registries with diagnostic results. These regional dynamics highlight both opportunities for targeted expansion and the importance of adaptable strategies in a diverse global environment.

In-Depth Assessment of Leading Organizations Driving Advances, Partnerships, and Competitive Strategies in the HLA Typing Ecosystem

In an increasingly competitive landscape, leading organizations are differentiating through a combination of strategic partnerships, portfolio expansion, and targeted innovation. Major instrument manufacturers are collaborating with software developers to deliver integrated solutions that streamline sample preparation, data acquisition, and analysis, reducing overall time to result. At the reagent level, companies are investing in proprietary chemistries that enhance assay sensitivity and reproducibility, enabling more reliable detection of low-frequency alleles.

Furthermore, several players are pursuing acquisitions that bolster their presence in emerging markets or expand capabilities into complementary diagnostic areas such as immunogenetics and pharmacogenomics. Concurrently, specialized firms are carving out niches by focusing exclusively on high-resolution sequencing assays, offering customizable panels that cater to unique transplantation protocols. These developments are underpinned by ongoing research collaborations with academic and clinical institutions, fostering a pipeline of next-generation platforms and novel biomarkers.

Collectively, these strategies reflect a shift toward end-to-end solutions that support the full lifecycle of HLA typing services. As competition intensifies, organizations that can effectively integrate hardware, consumables, software, and support services stand to gain a sustainable advantage in both established and developing markets.

Strategic Recommendations to Enhance Operational Efficiency, Foster Collaboration, and Accelerate Adoption of Next-Generation HLA Typing Solutions in Clinical Settings

To navigate the evolving HLA typing for transplant market, industry leaders should prioritize investments in workflow automation and digital integration. By adopting modular platforms that facilitate rapid assay expansion and seamless data transfer, laboratories can achieve greater throughput without compromising quality. In addition, forging strategic alliances with reagent suppliers and distribution partners will mitigate supply chain risks and ensure uninterrupted access to critical components.

Embracing open data standards and interoperable informatics infrastructures will enhance collaboration between transplant centers, diagnostic laboratories, and research networks, driving deeper insights and improved patient outcomes. Leaders should also explore opportunities in emerging markets by tailoring solutions to local epidemiological profiles, regulatory requirements, and budgetary constraints. Workforce development initiatives, including training programs for technical staff and bioinformatics specialists, are essential to maximize the potential of advanced typing methodologies.

Finally, engaging with regulatory agencies to shape evolving accreditation frameworks can streamline the pathway for novel technologies, while participation in professional consortia and standards committees will position organizations at the forefront of best practices. These actionable steps will empower stakeholders to capitalize on technological advances, optimize operational efficiencies, and deliver enhanced value across the transplant ecosystem.

Robust Multi-Phase Research Approach Detailing Data Collection, Validation Protocols, Analytical Frameworks, and Quality Controls Underpinning the HLA Typing Market Study

The research underpinning this executive summary combines primary and secondary methodologies to ensure a comprehensive and reliable analysis. Primary research involved in-depth interviews with transplantation experts, laboratory directors, and healthcare procurement specialists, supplemented by survey data from regional networks of transplant centers. This direct engagement provided nuanced perspectives on operational challenges, adoption drivers, and unmet needs across multiple geographies.

Secondary research encompassed a systematic review of peer-reviewed journals, regulatory filings, clinical guidelines, and technical white papers. Data extraction protocols were designed to capture the latest advancements in assay technologies, workflow innovations, and regulatory developments. Triangulation methods were employed to cross-verify findings, enhancing the accuracy of insights and minimizing potential biases.

Analytical frameworks included a strengths, weaknesses, opportunities, and threats examination of key segments, as well as a five forces assessment of the competitive environment. Quality control measures consisted of expert panel reviews and iterative validation cycles to refine conclusions. Together, these rigorous methods combine to deliver a robust foundation for strategic decision making within the HLA typing for transplant domain.

Synthesis of Core Findings Emphasizing Strategic Imperatives, Future Outlook, and Key Considerations for Stakeholders in the Evolving HLA Typing for Transplant Landscape

In synthesizing the core findings, it is evident that technological innovation and clinical demand are converging to redefine the HLA typing landscape for transplantation. The shift toward high-resolution, molecular-based assays is enabling more precise compatibility assessments, while software and automation are accelerating turnaround times and reducing manual errors. Simultaneously, evolving trade policies, exemplified by the 2025 tariffs, have prompted stakeholders to reevaluate procurement strategies and invest in supply chain resilience.

Segmentation analysis offers a granular understanding of market drivers across product, technology, transplant type, application, and end-user categories, guiding tailored approaches to product development and commercialization. Regional insights further contextualize these trends, highlighting the need for adaptable strategies that address the diverse regulatory, infrastructural, and economic conditions present in the Americas, Europe Middle East Africa, and Asia-Pacific. Leading organizations are responding through integrated offerings and strategic collaborations, setting the stage for differentiated growth.

Looking ahead, the successful navigation of regulatory landscapes, combined with targeted investments in digital and automated solutions, will be paramount to advancing transplant outcomes and driving market success. Stakeholders equipped with these insights will be well positioned to respond to emerging opportunities and maintain a competitive edge in the dynamic field of HLA typing for transplant.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Expansion of global donor registries coupled with big data analytics enhances HLA match prediction models
  • 5.2. Emerging point-of-care HLA typing platforms accelerate critical decision making in organ transplant centers
  • 5.3. Integration of artificial intelligence algorithms streamlines HLA allele interpretation in transplant laboratories
  • 5.4. Next-generation sequencing adoption drives high resolution HLA typing accuracy improvements for transplant matching
  • 5.5. Rise of single-cell sequencing technologies reshapes donor-recipient HLA compatibility assessment workflows
  • 5.6. Implementation of CRISPR-based genome editing strategies target HLA loci for tolerance induction research
  • 5.7. Standardization of regulatory guidelines and proficiency testing improves consistency in HLA typing quality control programs
  • 5.8. Development of ultra-high-throughput microarray solutions lowers costs and increases scalability of HLA typing assays
  • 5.9. Growing emphasis on non-HLA immunogenomic biomarkers enriches risk stratification for transplant rejection management
  • 5.10. Shift towards decentralized and automated HLA testing models reduces turnaround time in pre-transplant evaluation pipelines

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. HLA Typing for Transplant Market, by Product Type

  • 8.1. Introduction
  • 8.2. Instruments
    • 8.2.1. Electrophoresis Equipment
    • 8.2.2. Flow Cytometers
    • 8.2.3. PCR Systems
    • 8.2.4. Sequencers
  • 8.3. Reagents & Consumables
  • 8.4. Software

9. HLA Typing for Transplant Market, by Technology

  • 9.1. Introduction
  • 9.2. Molecular Assays
    • 9.2.1. Next-Generation Sequencing (NGS)
    • 9.2.2. PCR-based Methods
    • 9.2.3. Sanger Sequencing
  • 9.3. Non-molecular Assays
    • 9.3.1. Mixed Lymphocyte Culture (MLC)
    • 9.3.2. Serological Assays

10. HLA Typing for Transplant Market, by Transplant Type

  • 10.1. Introduction
  • 10.2. Hematopoietic Stem Cell Transplant (HSCT)
    • 10.2.1. Bone Marrow
    • 10.2.2. Peripheral Blood Stem Cells
  • 10.3. Solid Organ Transplant
    • 10.3.1. Heart
    • 10.3.2. Kidney
    • 10.3.3. Liver
    • 10.3.4. Lung

11. HLA Typing for Transplant Market, by Application

  • 11.1. Introduction
  • 11.2. Disease Association Studies
  • 11.3. Donor Recipient Matching
  • 11.4. Pharmacogenomics Research
  • 11.5. Transplant Diagnostics

12. HLA Typing for Transplant Market, by End user

  • 12.1. Introduction
  • 12.2. Blood Banks & Organ Procurement Organizations
  • 12.3. Diagnostic Laboratories
  • 12.4. Hospitals & Transplant Centers
  • 12.5. Research Laboratories

13. Americas HLA Typing for Transplant Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa HLA Typing for Transplant Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific HLA Typing for Transplant Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Agilent Technologies, Inc.
    • 16.3.2. Becton, Dickinson and Company
    • 16.3.3. Bio-Rad Laboratories, Inc.
    • 16.3.4. Abbott Laboratories
    • 16.3.5. Biofortuna Limited
    • 16.3.6. bioMerieux SA
    • 16.3.7. Bruker Corporation
    • 16.3.8. CareDx, Inc.
    • 16.3.9. Creative Biolabs
    • 16.3.10. Diasorin S.p.A.
    • 16.3.11. F. Hoffmann-La Roche Ltd
    • 16.3.12. Fujirebio Inc.
    • 16.3.13. GenDx B.V.
    • 16.3.14. HistoGenetics LLC
    • 16.3.15. Hologic, Inc.
    • 16.3.16. Illumina, Inc.
    • 16.3.17. Immucor, Inc. by WERFEN
    • 16.3.18. Omixon Biocomputing Ltd.
    • 16.3.19. PacBio
    • 16.3.20. QIAGEN N.V.
    • 16.3.21. Siemens Healthineers AG
    • 16.3.22. Takara Bio Inc.
    • 16.3.23. Thermo Fisher Scientific Inc.

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. HLA TYPING FOR TRANSPLANT MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. HLA TYPING FOR TRANSPLANT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. HLA TYPING FOR TRANSPLANT MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. HLA TYPING FOR TRANSPLANT MARKET: RESEARCHAI
  • FIGURE 26. HLA TYPING FOR TRANSPLANT MARKET: RESEARCHSTATISTICS
  • FIGURE 27. HLA TYPING FOR TRANSPLANT MARKET: RESEARCHCONTACTS
  • FIGURE 28. HLA TYPING FOR TRANSPLANT MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. HLA TYPING FOR TRANSPLANT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY ELECTROPHORESIS EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY ELECTROPHORESIS EQUIPMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY FLOW CYTOMETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY FLOW CYTOMETERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED METHODS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MIXED LYMPHOCYTE CULTURE (MLC), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MIXED LYMPHOCYTE CULTURE (MLC), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEROLOGICAL ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEROLOGICAL ASSAYS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY BONE MARROW, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PERIPHERAL BLOOD STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PERIPHERAL BLOOD STEM CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEART, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEART, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY KIDNEY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY KIDNEY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY LIVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY LIVER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY LUNG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY LUNG, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DISEASE ASSOCIATION STUDIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DISEASE ASSOCIATION STUDIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DONOR RECIPIENT MATCHING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DONOR RECIPIENT MATCHING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PHARMACOGENOMICS RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PHARMACOGENOMICS RESEARCH, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY BLOOD BANKS & ORGAN PROCUREMENT ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY BLOOD BANKS & ORGAN PROCUREMENT ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 90. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 91. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 92. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 93. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 94. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 95. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 97. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 99. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2025-2030 (USD MILLION)
  • TABLE 101. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2025-2030 (USD MILLION)
  • TABLE 103. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2025-2030 (USD MILLION)
  • TABLE 105. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 107. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 109. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 111. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 113. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 114. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 115. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 116. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 117. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 118. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 119. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 120. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 121. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2024 (USD MILLION)
  • TABLE 122. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2025-2030 (USD MILLION)
  • TABLE 123. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2018-2024 (USD MILLION)
  • TABLE 124. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2025-2030 (USD MILLION)
  • TABLE 125. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 126. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2025-2030 (USD MILLION)
  • TABLE 127. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 128. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 129. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 130. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 131. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 132. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 133. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 135. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 136. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 137. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 138. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 139. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 140. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 141. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 142. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 143. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2025-2030 (USD MILLION)
  • TABLE 145. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2018-2024 (USD MILLION)
  • TABLE 146. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2025-2030 (USD MILLION)
  • TABLE 147. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 148. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2025-2030 (USD MILLION)
  • TABLE 149. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 150. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 151. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 152. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 153. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 155. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 156. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 157. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 158. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 159. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 160. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 161. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 162. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 163. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2025-2030 (USD MILLION)
  • TABLE 165. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2018-2024 (USD MILLION)
  • TABLE 166. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2025-2030 (USD MILLION)
  • TABLE 167. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 168. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2025-2030 (USD MILLION)
  • TABLE 169. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 170. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 171. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 173. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 175. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 176. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 177. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 178. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 179. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 180. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 181. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 182. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 183. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2025-2030 (USD MILLION)
  • TABLE 185. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2018-2024 (USD MILLION)
  • TABLE 186. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2025-2030 (USD MILLION)
  • TABLE 187. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 188. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2025-2030 (USD MILLION)
  • TABLE 189. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 190. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 191. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 193. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 195. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 196. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 197. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 198. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 199. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 200. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 201. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 202. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 203. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2025-2030 (USD MILLION)
  • TABLE 205. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2018-2024 (USD MILLION)
  • TABLE 206. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2025-2030 (USD MILLION)
  • TABLE 207. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 208. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2025-2030 (USD MILLION)
  • TABLE 209. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 210. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 211. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2025-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2025-2030 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2025-2030 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. UNITED KINGDOM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 238. UNITED KINGDOM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 240. UNITED KINGDOM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 242. UNITED KINGDOM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 243. UNITED KINGDOM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 244. UNITED KINGDOM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 245. UNITED KINGDOM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. UNITED KINGDOM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2025-2030 (USD MILLION)
  • TABLE 247. UNITED KINGDOM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2018-2024 (USD MILLION)
  • TABLE 248. UNITED KINGDOM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2025-2030 (USD MILLION)
  • TABLE 249. UNITED KINGDOM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED KINGDOM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2025-2030 (USD MILLION)
  • TABLE 251. UNITED KINGDOM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED KINGDOM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 253. UNITED KINGDOM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. UNITED KINGDOM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 255. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 257. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 258. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 259. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 261. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 262. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 263. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 264. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 265. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2025-2030 (USD MILLION)
  • TABLE 267. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2018-2024 (USD MILLION)
  • TABLE 268. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2025-2030 (USD MILLION)
  • TABLE 269. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 270. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2025-2030 (USD MILLION)
  • TABLE 271. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 272. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 273. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 275. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 277. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 278. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 279. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 280. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 281. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 282. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 283. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 284. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 285. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2025-2030 (USD MILLION)
  • TABLE 287. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2018-2024 (USD MILLION)
  • TABLE 288. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2025-2030 (USD MILLION)
  • TABLE 289. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 290. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2025-2030 (USD MILLION)
  • TABLE 291. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 292. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 293. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 295. RUSSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. RUSSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 297. RUSSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 298. RUSSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 299. RUSSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 300. RUSSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 301. RUSSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 302. RUSSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 303. RUSSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 304. RUSSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 305. RUSSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. RUSSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLAN